BioXcel Therapeutics
BTAI
73 hedge funds and large institutions have $26.1M invested in BioXcel Therapeutics in 2024 Q1 according to their latest regulatory filings, with 11 funds opening new positions, 18 increasing their positions, 25 reducing their positions, and 11 closing their positions.
0% more funds holding
Funds holding: 73 → 73 (0)
0% more first-time investments, than exits
New positions opened: 11 | Existing positions closed: 11
0.28% less ownership
Funds ownership: 2% → 1.72% (-0.28%)
6% less capital invested
Capital invested by funds: $27.6M → $26.1M (-$1.54M)
28% less repeat investments, than reductions
Existing positions increased: 18 | Existing positions reduced: 25
44% less call options, than puts
Call options by funds: $422K | Put options by funds: $754K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Armistice Capital
New York
|
+$1.11M |
| 2 |
UBS Group
Zurich,
Switzerland
|
+$295K |
| 3 |
CP
Castleview Partners
Dallas,
Texas
|
+$290K |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$269K |
| 5 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
+$143K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Adage Capital Partners
Boston,
Massachusetts
|
-$1.37M |
| 2 |
AWA
Arete Wealth Advisors
Chicago,
Illinois
|
-$322K |
| 3 |
Bank of America
Charlotte,
North Carolina
|
-$170K |
| 4 |
Squarepoint
New York
|
-$168K |
| 5 |
BlackRock
New York
|
-$138K |
BTAI Hedge Fund Activity: Q1 2024 in Review
73 of the 6,958 institutional investors tracked by Wall St. Rank reported a position in BioXcel Therapeutics (BTAI) for Q1 2024, worth a combined $26.1M — down 5.6% from $27.6M a quarter earlier.
Fund positioning in BTAI was balanced in Q1 2024: 11 funds opened new positions, 11 closed out, 18 added to existing stakes and 25 trimmed.
The largest buyer was Armistice Capital, opening a new position worth an estimated $1.11M. The largest seller was Adage Capital Partners, exiting entirely with an estimated $1.37M sold.
- 73 institutional investors held BioXcel Therapeutics (BTAI) as of Q1 2024, unchanged from Q4 2023.
- Funds reported $26.1M of BioXcel Therapeutics stock for Q1 2024, down 5.6% quarter-over-quarter.
- 11 funds opened new BioXcel Therapeutics positions in Q1 2024 and 11 closed out, a net change of 0 holders.
- The largest BioXcel Therapeutics buyer in Q1 2024 was Armistice Capital, an estimated $1.11M added.
- The largest BioXcel Therapeutics seller in Q1 2024 was Adage Capital Partners, an estimated $1.37M sold.
Based on aggregated 13F filings for Q1 2024.